“The North America breast reconstruction market is anticipated to reach USD 616.37 Million by 2030”, says Visiongain

29 November 2019
Pharma

Visiongain has launched a new pharma report ‘’North America Breast Reconstruction Market Report 2020-2030’’ by Product {Implants, Tissue Expander (Saline Breast Implants, Silicone Breast Implants)}, Shape (Anatomical, Round), and Geography.

The North America breast reconstruction market is anticipated to grow at a lucrative CAGR of 4.8% and anticipated to reach USD 616.37 Million by 2030.

The growing number of reconstruction procedures coupled with growing breast cancer prevalence and the introduction of technologically advanced products across the region is anticipated to fuel market growth over the forecast period from 2020 to 2030.

It is also anticipated that growing awareness and concerns about physical appearance would lead to market growth. For example, according to a recent study conducted by the NCBI (National Center for Biotechnology Information), along with physical appearance, post-mastectomy breast reconstruction also improves women's self-esteem and psychologically supports them. This has resulted in increased growth of these products due to the high demand for surgical procedures.

The most common form of cancer in women is breast cancer. Breast cancer is mostly marked by breast lump growth, inverted nipple, a shift in breast shape, fluid from the nipple, or red or scaly skin patch, skin dimpling, and breast pain, or sore nipple. Mastectomy is a breast cancer treatment technique that involves removing the whole breast through a surgical operation. Following mastectomy, breast reconstruction procedure is used to repair the breasts.

The two main methods for breast reconstruction are implant reconstruction and autologous or flap reconstruction. Most women have opted for reconstruction procedures in recent years to recover following mastectomy the original shape of their breasts. This growing preference is expected in the coming years to boost the market growth.

Likewise, in the UK, as many as 691,000 women diagnosed with breast cancer are alive, according to the breastcancercare.org.uk. It is estimated that this number will exceed 840,000 by 2020. Similar trends of increase in the number of cases of breast cancer have been observed in other parts of the world and this development, driven by growing demand for reconstruction procedures, is expected to improve the market during the forecast period.

Also, it is expected that the increasing prevalence of breast cancer around the globe will be another key driver for breast reconstruction process growth. As of January 2018, more than 3.1 million women in the U.S. were reported with a history of breast cancer, including the patients currently undergoing treatment, as well as completing their treatment.

In the year 2018, silicone breast implants dominated the North America breast reconstruction market and a similar trend is anticipated over the forecast period. The outer surfaces of these devices are lined with a silicone gel which is available in various sizes and are smooth or textured. The Food and Drug Administration (FDA) approves silicone implants for breast reconstruction for women of all ages. Such implants are also used for breast cancer post-mastectomy. Because of their appearance as natural breast tissue & soft texture, women prefer silicone implants.

Because of the soft texture of silicone implants, there is minimal risk of development of hard scar tissue around the implant. These also present minimal risk of any conditions associated with the immune system.

North America dominated the global breast reconstruction market in 2018 and the region is anticipated to grow at a lucrative CAGR till 2030. An increasing the number of mastectomies due to increased breast cancer incidence & prevalence is one of the major factors driving market growth in the North American region. However, it is also anticipated that the emergence of highly developed healthcare infrastructure and increasing healthcare spending will drive the market further over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global circulating tumor cells market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Breast Reconstruction market.

For instance, Sientra Inc. received approval from the U.S. Food and Drug Administration (FDA) for the PMA supplement permitting the commercialization of OPUS-branded breast implant products which are manufactured by Vesta, a Lubrizol LifeSciences company.

The comprehensive market report features companies such as Allergan Inc., IDEAL IMPLANT INCORPORATED, Mentor Worldwide LLC, Sientra, Inc., POLYTECH Health & Aesthetics GmbH, CEREPLAS, Establishment Labs S.A, Guangzhou Wanhe Plastic Materials Co., Ltd, GROUPE SEBBIN SAS, Shanghai Kangning Medical Supplies Ltd, GC Aesthetics, PMT Corporation, Arion Laboratories, AirXpanders, Inc., HANSBIOMED CO. LTD among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever